General description: Established in 1995, Biomatlante develops, manufactures and commercializes synthetic bone substitutes used in orthopaedic, spine, maxillo facial and dental surgery fields. The company currently employs 48 people including 3 PhD. In the full-year 2008, the turnover reached 3 158 K€.
Website: www.biomatlante.com
Expertise: Biomatlante’s expertise and know-how is based on micro macroporous biphasic calcium phosphate (MBCP®) bone substitute allowing in-depth cellular colonization and bone growth at the expense of the bioceramic (1). This product is available as blocks of different shapes, granules, non-hardening injectable version (MBCP Gel) (2), self-hardening mouldable composite with fibrin glue (TricOs™, a Baxter-Biomatlante partnership development) (3) as well as specific scaffolds for drug delivery and tissue engineering (4, 5). In addition, Biomatlante has developed composite implants which consist of a mixture of resorbable bio-polymers and calcium phosphates. These products provide an intrinsic mechanical strength which allows the development of resorbable osteosynthetic systems such as interference screws and fusion cages.
Facilities: clean rooms, X-ray diffractometer, sintering ovens, materials testing machine, injection press machine
Other European projects: REBORNE-Project No. 241879- ongoing negotiation
Role in the project: Biomatlante will contribute to the GAMBA project by:
- optimising biphasic calcium phosphate granules as carriers for gene vectors
- developping injectable calcium phosphate ceramics by combination with hydrosoluble polymers
- defining packaging and sterilisation processes for the “gene delivery system”
Workpackages responsibilty: Development and optimisation of MBCP carriers for gene vectors; optimisation of processes for manufacturing
WP01, WP02, WP03, WP05, WP06, WP07 (bold = WP leader; WP = Workpackage)
Chantal Gobin: (F), Président. Expertise in management and sterilisation processes. She is the legal entity authorized representative.
Pascal Borget: (M), PhD, R&D project Manager. Expertise in Physical Chemistry of biomaterials (polymers, CaP). He will be the scientific manager.
Cecile Charrier: (F), Administrative manager. Expertise in accounting. She will be the financial manager.
Guy Daculsi: (M) Prof., Research director INSERM, is scientific advisor to Biomatlante.
One doctorate will eventually be hired by Biomatlante.
Publications:
-
Daculsi G, Laboux O, Malard O, Weiss P. J. Mater. Sci. Mater. Medecine 2003, 14:195-200
-
Daculsi G, Weiss P, Bouler JM, Gauthier O, Aguado E. Bone 1999, 25:59-61
-
Le Guehennec L, Goyenvalle E, Aguado E, Pilet P, Bagot d’Arc M, Bilban M, Spaethe R, Daculsi G. J. Mater. Sci. Mater. Medecine 2005, 16:29-35
-
Smuckere JD, Aggarwal D, Zamora PO, Atkinson BL, Bobst JA, Nepola JV Fredericks DC. Proceeding of AAOS annual congress, San Diego 2007
-
Arinzeh TL, Tran T, McAlary J, Daculsi G. Biomaterials 2005, 26(17):3631-8
Patents:
|
Owner |
Reference number |
Period of validity |
Title |
|
CNRS/University of Nantes |
94 014 14 |
20 years from 8 february 1994 |
MBCP Gel |
|
Biomatlante |
06/10064 |
20 years from 17 november 2006 |
New Gel |
|
Biomatlante |
0753590 |
20 years from 1 march 2007 |
Freeze-dried hydrogel |
Specific awards and certifications: ISO 13485
